Richter syndrome and cancer
Richter syndrome is a rare and aggressive form of cancer that primarily affects adults under fifty-five, emerging as a transformation from chronic lymphocytic leukemia (CLL) into diffuse large B-cell lymphoma (DLBCL). While CLL is a cancer of the blood characterized by the accumulation of abnormal lymphocytes, Richter syndrome signifies a critical advancement of the disease, leading to rapid health deterioration and often resulting in severe symptoms, including fatigue, fever, and significant weight loss. The incidence of Richter syndrome is notably low, occurring in just 1 to 10 percent of CLL patients, with a higher prevalence among men and younger individuals.
The precise cause of Richter syndrome remains unknown, although risk factors such as the Epstein-Barr virus and genetic predispositions may contribute to its development. Diagnosis typically involves a combination of microscopic examination, bone marrow biopsy, and imaging tests to evaluate the extent of the disease. Treatment options are challenging due to the aggressive nature of the cancer, often involving chemotherapy regimens like R-CHOP or experimental approaches like CAR-T Cell Therapy. Unfortunately, the prognosis is generally poor, with less than a year of survival post-diagnosis, emphasizing the critical need for ongoing research and advancements in therapeutic strategies.
On this Page
Subject Terms
Richter syndrome and cancer
ALSO KNOWN AS: Diffuse large-cell lymphoma, diffuse large B-cell lymphoma, Richter transformation, Richter’s syndrome
RELATED CONDITIONS: Chronic lymphocytic leukemia (CLL), high-grade non-Hodgkin lymphoma (NHL)
DEFINITION: Richter syndrome, named after Maurice Nathaniel Richter, an American pathologist, is a very rare type of cancer that primarily affects adults under the age of fifty-five. Leukemia is a cancer of the white blood cells, and Richter syndrome is an advanced type of lymphocytic leukemia that starts in the bone marrow as chronic lymphocytic leukemia but develops or transforms into diffuse large B-cell lymphoma (DLBCL). This transformation of the cancer type is very aggressive and has the ability to travel through the blood and access the entire body. When chronic lymphocytic leukemia transforms into diffuse large-cell lymphoma, it does so quickly and causes sudden deterioration of the patient’s health, which leads to an extreme exacerbation of symptoms and often to the death of the patient.
Risk factors: To develop Richter syndrome, a person first must have chronic lymphocytic leukemia (CLL), a rare cancer of the blood, though only between 1 and 10 percent of CLL patients develop Richter syndrome. The Epstein-Barr virus may play a role in triggering the transformation of CLL to DLBCL. Some genetic influence may also play a role in the transformation of CLL to diffuse large-cell lymphoma. However, it is important to remember that these risk factors are not determinants but have been shown to be related to Richter syndrome.
Etiology and the disease process: There is no known cause for Richter syndrome. Onset of Richter syndrome or the transformation of chronic lymphocytic leukemia to diffuse large-cell lymphoma is thought to be typically brought about by a variation in the patient’s lymphocytes accompanied by rapid tumor growth, swelling of lymph nodes, fever, and weight loss caused by a reduction in appetite. Richter syndrome usually develops between two and four years after the initial CLL diagnosis.
Incidence: Cases of Richter syndrome are extremely rare, occurring in only between 1 and 10 percent of patients with the aggressive form of non-Hodgkin lymphoma, CLL. In general, incidence is higher among men and those younger than fifty-five.
Symptoms: Symptoms of lymphoma include swelling of the lymphatic system, particularly swelling of the lymph nodes in the neck, armpit, or groin. Symptoms of Richter syndrome often include fatigue, decreased appetite, fever, night sweating, weight loss, and breathlessness. These symptoms may manifest rapidly.
Screening and diagnosis: Screening for Richter syndrome is performed on patients with CLL who are judged to be at risk of developing the syndrome. Diagnosis of Richter syndrome is done through microscopic examination of cells and biopsy of the bone marrow of a select “flat” bone, including bones of the rib, hip, and shoulder. Further tests include blood tests, bone scans, lymph node biopsy, and X-rays to assess the cancer and its spread within the body.
Treatment and therapy: Treatment for Richter syndrome is typically chemotherapy; however, because this cancer is very aggressive, chemotherapy often is not successful. Bone marrow transplantation is also a potential treatment, but this option is rare and usually occurs within clinical trials.
The two medications typically used to treat diffuse large-cell lymphoma are doxorubicin and cyclophosphamide. These drugs are often used in combination with radiation. Another popular treatment option is called the R-CHOP regimen, which consists of a monoclonal antibody and four types of chemotherapy. Monoclonal antibodies are used to improve the body’s immune response. Additionally, supportive therapies, such as steroids, are used to help alleviate the side effects of the aggressive medicinal regimen.
Much progress has been made in treating this aggressive condition in the twenty-first century. Targeted agents, including BTK inhibitors, BCL2 inhibitors, and PD1-PDL1 inhibition, have been shown to cause a favorable reaction in 50 percent of patients. When combined with immunotherapy, the effectiveness of these agents grew. CAR-T Cell Therapy, found to be successful in treating blood and other types of cancer, was being tested on patients with Richter syndrome. Finally, high-dose chemotherapy followed by stem cell transplant was shown to place some patients in remission.
Prognosis, prevention, and outcomes: The prognosis for Richter syndrome is survival for less than one year following diagnosis, as patients with Richter syndrome typically do not respond well to treatment because of the advanced state of their cancer, as well as their depressed immune response. As genetic factors play a role in this cancer, prevention steps are limited but include maintaining a healthy lifestyle without the use of tobacco products and exposure to pesticides, herbicides, and radiation.
Bibliography
Catovsky, D., J. Fooks, and S. Richards. “Prognostic Factors in Chronic Lymphocytic Leukaemia: The Importance of Age, Sex, and Response to Treatment in Survival: A Report from the MRC CLL 1 Trial.” British Journal of Haematology, vol. 72.2, 1989, pp. 141–49.
Douglas, Melanie. "Richter Transformation: Clinical Manifestations, Evaluation, and Management." Journal of the Advanced Practitioner in Oncology, vol. 13, no. 5, 2022, pp. 525-534, doi.org/10.6004/jadpro.2022.13.5.6. Accessed 16 June 2024.
“Richter's Syndrome - Non-Hodgkin Lymphoma.” Cancer Research UK, 19 Apr. 2024, www.cancerresearchuk.org/about-cancer/non-hodgkin-lymphoma/types/richters-syndrome. Accessed 16 June 2024.
Robertson, L. E., et al. “Richter’s Syndrome: A Report on Thirty-nine Patients.” Journal of Clinical Oncology, vol. 11.10, 1993, pp. 1985–89.
Rodriguez, J., et al. “Allogeneic Haematopoietic Transplantation for Richter’s Syndrome.” British Journal of Haematology, vol. 110.4, 2000, pp. 897–99.
Rossi, D., and G. Gaidano. "Richter Syndrome." Advances In Experimental Medicine and Biology, vol. 792, 2013, pp. 173–91.
Ryan, Christine. “Practical Management of Richter Transformation in 2023 and Beyond.” American Society of Clinical Oncology Educational Book, vol. 43, 2023. ASCO Publications, doi.org/10.1200/EDBK‗390804. Accessed 16 June 2023.
Souhami, Robert L., et al., eds. Oxford Textbook of Oncology. 2d ed. New York: Oxford UP, 2002.
Tsimberidou A. M., and M. J. Keating. “Richter Syndrome: Biology, Incidence, and Therapeutic Strategies.” Cancer, vol. 103.2, 2005, pp. 216–28.
Wu, Catherine. “Scientists Map Genetic Evolution of Chronic Lymphocytic Leukemia to Richter's Syndrome.” Dana-Farber Cancer Institute, 11 Dec. 2022, www.dana-farber.org/newsroom/news-releases/2022/scientists-map-genetic-evolution-of-chronic-lymphocytic-leukemia-to-richter-s-syndrome. Accessed 16 June 2024.